Figure 2.
Forest plots of multivariable Cox regression models for OM within 1 year after CARTx. Forest plots of models incorporating (A) CAR T-cell target (CD19/CD20 vs BCMA), CRS and/or ICANS grade ≥2, CMV reactivation (any level) detected within 6 weeks of CARTx; (B) CAR T-cell target (CD19/CD20 vs BCMA), corticosteroid use for >3 days, and CMV reactivation (any level) detected within 6 weeks of CARTx; and (C) CAR T-cell target (CD19/CD20 vs BCMA), CRS and/or ICANS grade ≥2, and CMV reactivation ≥150 IU/mL detected within 6 weeks of CARTx. (D) CAR T-cell target (CD19/CD20 vs BCMA), corticosteroid use for >3 days, and csCMV reactivation ≥150 IU/mL detected within 6 weeks of CARTx. Survival analysis including data on 82 participants. CRS, cytokine release syndrome; HR, hazard ratio; ICANS, immune effector cell–associated neurotoxicity syndrome.

Forest plots of multivariable Cox regression models for OM within 1 year after CARTx. Forest plots of models incorporating (A) CAR T-cell target (CD19/CD20 vs BCMA), CRS and/or ICANS grade ≥2, CMV reactivation (any level) detected within 6 weeks of CARTx; (B) CAR T-cell target (CD19/CD20 vs BCMA), corticosteroid use for >3 days, and CMV reactivation (any level) detected within 6 weeks of CARTx; and (C) CAR T-cell target (CD19/CD20 vs BCMA), CRS and/or ICANS grade ≥2, and CMV reactivation ≥150 IU/mL detected within 6 weeks of CARTx. (D) CAR T-cell target (CD19/CD20 vs BCMA), corticosteroid use for >3 days, and csCMV reactivation ≥150 IU/mL detected within 6 weeks of CARTx. Survival analysis including data on 82 participants. CRS, cytokine release syndrome; HR, hazard ratio; ICANS, immune effector cell–associated neurotoxicity syndrome.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal